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BACKGROUND: Primary care providers (PCPs) must
balance treatment of chronic non-cancer pain with
opioid analgesics with concerns about opioid misuse.
OBJECTIVE: We co-enrolled community-based indigent
adults and their PCPs to determine PCPs’ accuracy of
estimating opioid analgesic misuse and illicit substance
use.
DESIGN: Patient-provider dyad study.
PARTICIPANTS: HIV-infected, community-based indi-
gent adults (‘patients’) and their PCPs.
MAIN MEASURES: Using structured interviews, we
queried patients on use and misuse of opioid analgesics
and illicit substances. PCPs completed patient- and
provider-specific questionnaires. We calculated the sen-
sitivity, specificity, and measures of agreement between
PCPs’ judgments and patients’ reports of opioid misuse
and illicit substance use. We examined factors associ-
ated with PCPs’ thinking that their patients had mis-
used opioid analgesics and determined factors
associated with patients’ misuse.
KEY RESULTS: We had 105 patient-provider dyads. Of
the patients, 21 had misused opioids and 45 had used
illicit substances in the past year. The sensitivity of
PCPs’ judgments of opioid analgesic misuse was 61.9%
and specificity, 53.6% (Kappa score 0.09, p=0.10). The
sensitivity of PCPs’ judgments of illicit substance use
was 71.1% and specificity, 66.7% (Kappa score 0.37,
p <0.001). PCPs were more likely to think that younger
patients (Adjusted odds ratio (AOR) 0.89, 95% CI 0.84-
0.97), African American patients (AOR 2.53, 95% CI
1.05-6.07) and those who had used illicit substances in
the past year (AOR 3.33, 95% CI 1.35-8.20) had
misused opioids. Younger (AOR 0.94, 95% CI 0.86-
1.02) and African American (AOR 0.71, 95% CI 0.25-
1.97) patients were not more likely to report misuse,
whereas persons who had used illicit substances were
(AOR 3.01, 95% CI 1.04-8.76).
CONCLUSION: PCPs’ impressions of misuse were dis-
cordant with patients’ self-reports of opioid analgesic
misuse. PCPs incorrectly used age and race as pre-
dictors of misuse in this high-risk cohort.
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INTRODUCTION
Chronic non-cancer pain (CNCP) is commonamongprimarycare
patients. There has been a rise in prescription opioid analgesic
use for the treatment of CNCP
1,2, and a rise in opioid analgesic
misuse, with a prevalence of 9% to 41% in patients treated with
opioid analgesics for CNCP
3–6. Patients with HIV/AIDS have a
high prevalence of chronic pain (prevalence 40%-60%), mental
health, and substance use disorders
11–14. On the one hand,
mental health and substance use disorders are associated with
opioid analgesic misuse
7–9, and on the other hand, they are also
risk factors for under treatment of pain in HIV-infected
patients
10,11. Clinicians must rely on existing tools and their
judgment of patients’ likelihood of misuse before continuing to
prescribe opioid analgesics. Studies have shown that clinicians
judge non-white patients to have a higher risk for prescription
opioid misuse when compared to white patients
15,16. However,
existing data do not support these beliefs
7,8.
There are several risk stratification tools that rely on patients’
self-reports of misuse
17–22; none have adequate sensitivity and
specificity to guide treatment decisions
23. Clinicians can use
urine toxicology screens, pill and patch counts to measure
adherence and monitor for use of non-prescribed opioid analge-
sics or illicit substances
24. A recent systematic review found
insufficient evidence for routine urine toxicology testing because
of the difficulty interpreting negative tests, which could indicate
diversion, inadequate treatment of pain, or inadequate test
sensitivity
24–26. Another element of risk assessment is clinicians’
impressions. Few studies have examined clinicians’ impressions
of misuse
27, and none have directly compared clinicians’
opinions of misuse to patients’ self-reports.
We conducted a patient–provider dyad study, co-enrolling
members of a representative community-based cohort of indi-
gent adults with HIV-infection and their primary care providers
(PCPs) to determine the concordance and discordance of PCPs’
judgments about prescription opioid misuse and illicit sub-
stance use compared to patients’ self-reports. We hypothesized
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412that PCPs’ estimates of misuse would have a low concordance
with patients’ self-reports. We hypothesized that PCPs would
overestimate risk in African American patients, while under-
estimating risk in white patients.
METHODS
Study Patients and Sampling
We enrolled patient participants (“patients”) into the dyad
study from a two-year longitudinal study of pain, use and
misuse of opioid analgesics in a community-based sample of
indigent adults (Pain Study). We recruited members of the Pain
Study from the pre-existing Research on Access to Care in the
Homeless (REACH) study, a longitudinal study of HIV-infected
adults in San Francisco who were systematically sampled from
homeless shelters, free meal programs, and low-rent single-
room occupancy hotels
28. We offered participation, regardless
of pain status, to all active REACH members between Septem-
ber 2007 and June 2008 (n=337); 296 (87.8%) completed
enrollment and baseline activities.
One year into the Pain Study, we began enrolling primary
care providers (PCPs) identified by Pain Study patients. We
recruited the PCP that each study patient identified, if the
patient gave informed consent and the identified PCP met our
definition (physician, Nurse Practitioner (NP), or Physician
Assistant (PA) providing longitudinal, comprehensive care).
All study protocols were reviewed and approved by the
University of California, San Francisco (UCSF), Institutional
Review Board; we obtained a Certificate of Confidentiality from
the National Institute on Drug Abuse. We told both patients
and PCPs that the information they provided would be kept
anonymous and not shared with the other party.
Study Procedures
We conducted data collection from the patients at the UCSF
Clinical and Translational Research Institute’sT e n d e r l o i n
Clinical Research Center (TCRC), a community-based univer-
sity-research site. Trained research assistants administered
the Pain Study and REACH study questionnaires every three
months. At the baseline Pain Study interview, a trained
interviewer administered the Diagnostic Interview Schedule—
IV (DIS-IV) substance modules (cocaine, methamphetamine,
and heroin)
29. At each REACH study quarterly visit, trained
interviewers obtained information on current illicit substance
use. At each Pain Study quarterly visit, patients answered
questions about prescription opioid analgesic misuse using
Audio Computer Assisted Self-Interview (ACASI) technology
30.
We recruited and collected data from PCPs by mail, using a
modified version of Dillman’s Tailored Design Method
31. PCPs
completed a short, provider-specific questionnaire and a
separate patient-specific questionnaire for each of their dyad-
study patients. PCPs were encouraged, but not required, to
access their patients’ medical records while completing the
patient-specific questionnaires.
We reimbursed patients $20.00 for the baseline Pain
Study interview, $5.00 for each Pain Study quarterly
interview, and $20.00 for each REACH study quarterly
interview. PCPs received a $10.00 gift certificate for each
completed questionnaire.
Variable Definitions
Patients. At the baseline Pain Study and REACH study visits,
patients self-reported information on demographics (age and
sex), race/ethnicity (white, African American, Hispanic, or
mixed/other), residential stability, jail and prison stays, mean
monthly income, insurance status (Medicaid/ Medicare, AIDS
Drug Assistance Program (ADAP), or uninsured), and lifetime
tobacco history (smoked at least 100 cigarettes in lifetime). We
administered the Beck Depression Inventory – II (BDI) and
classified depression as moderate to severe (BDI score >19) or
noneormild(BDIscore≤19)
32,33. Weadministered the BriefPain
Inventory (BPI)
34, and using patients’ self-reports of average
intensity of pain in the past 7 days and cut-point analysis, we
classified pain as mild (0-3), moderate (4-5), or severe (6-10)
35.
We created an inventory of opioid analgesic misuse behaviors
that have been previously described in the literature
14,36–38.W e
defined opioid analgesic misuse as getting high, altering the
route, selling, stealing, forging prescriptions, trading street
drugs for opioids, and exchanging opioids for sex in the past
90 days. We used patients’ ACASI self-reports of misuse from
four quarterly interviews to create a dichotomous variable that
measured past-year misuse. We created a variable that
combined responses for getting high, altering the route or
selling prescription opioids (“o n eo rm o r em i s u s eb e h a v i o r s ”)t o
mirror what we had asked PCPs.
We obtained self-reports of illicit substance use (cocaine,
methamphetamine, and heroin) in the past 90 days from the
REACH quarterly interviews, and created a dichotomous variable
of any illicit substance use in the past year based on four
quarterly interviews. We diagnosed lifetime substance abuse or
dependence for cocaine, methamphetamine, and heroin using
the DIS-IV instrument
29. We used the DIS-IV question, “Which
one of these have you used more than five times when they were
not prescribed for you, or for longer than prescribed, to feel more
active or alert, or to feel good or high?” to define lifetime
substance use of cocaine, methamphetamine, and heroin.
Primary Care Providers
In the provider-specific questionnaires, PCPs answered ques-
tions on demographics (age and sex), race/ethnicity (white,
African American, Hispanic, or Asian/Pacific Islander), clinical
training (physician, NP or PA), specialty for physicians (inter-
nists, family practice or other), subspecialty for internists
(Infectious disease (ID) or HIV), and years in clinical training
(4 to 9 years, 10 to 19 years, ≥20 years).
In the patient-specific questionnaire, PCPs reported wheth-
er they had prescribed that patient an opioid analgesic, and
whether they had ordered urine or blood toxicology screens.
Using a 5-point Likert scale, PCPs reported whether their
study patient had misused opioid analgesics by getting high,
altering the route, or selling these medications. We classified
responses as affirmative (maybe, probably or definitely) versus
negative (probably not or definitely not). We asked PCPs’ to
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patients they were responding for had used individual illicit
substances (cocaine, methamphetamine, and heroin). We
created a variable that measured PCPs’ composite affirmative
responses of any illicit substance use in the past year for each
patient under their care.
Statistical Analysis
We compared dyad-study patients’ self-reports of opioid anal-
gesic misuse or illicit substance use with their corresponding
PCPs’ assessments. We matched the date that the PCP
completed the patient-specific questionnaire to the closest-
occurring quarterly interview completed by the patient, and
included three prior quarterly interviews to create a one-year
assessment time period.
We restricted our analysis to patients who were prescribed an
opioid analgesic in the past year based on PCPs’ reports. We
calculated the sensitivity and specificity of PCPs’ opinions of
opioid analgesic misuse and illicit substance use compared to
patients’ self-reports, and used the Kappa statistic to measure
concordance between PCPs’ opinions and patients’ self-reports.
We used logistic regression to examine patient factors that
were associated with PCPs’ thinking that their patients had
misused prescription opioid analgesics in the past year. We used
patients’ age, sex, race (African American versus non-African
American) and history of illicit substance use in the past year as
independent variables as these have been shown to predict
opioid misuse or to be associated with PCPs’ perception of
misuse in prior studies. We then determined if any of these
factors were independent predictors of patients’ self-reports of
past-year misuse. All analyses were conducted using Stata
software, version 11.
RESULTS
Sample Characteristics
Ofthe296patientsinitiallyenrolledintheparentPainStudy,272
(91.9%) were active in follow-up during data collection for the
dyad study, of whom 269 (98.9%) provided written consent
allowing us to contact their PCP (Fig. 1). Of these, 240 (89.3%)
named a provider who fit the definition of PCP and had
confirmable contact information. The 240 patients identified 90
unique PCPs from 23 clinical settings. We obtained responses
from61PCPs(67.8%)whorespondedon169patients(70.4%).Of
these 169 patients, 105 (62.1%) were prescribed an opioid
analgesic by PCPs in the past year. Of the 105 patients, 80.8%
(n=84) were prescribed an opioid analgesic for treatment of
chronic pain withthe intention oftakingthe medication regularly
for more than one month. PCPs reported ordering urine or blood
toxicology screens on 27.6% of patients in the past year. We
reported results on 105 patient-provider dyads.
The mean age of the patients who were prescribed an
opioid analgesic in the past year was 50 (Table 1). The
majority of patients were male (61.9%), and 48.6% were
296 patients were enrolled in the 
Pain Study.
240 patients (89.3%) named 90 primary care 
providers who met the study definition.
272 patients (91.9%) were active in 
the Pain Study after 1 year.
269 patients (98.9%) consented to 
participate in the Dyad Study.
61 PCPs (67.8%) completed questionnaires about 
169 patients (70.4%). 
105 patients (62.1%) were prescribed 
an opioid analgesic in the past year by 
their PCPs.
64 patients (37.9%) were not 
prescribed an opioid analgesic in the 
past year by their PCPs.
Figure 1. Patient flow.
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school. Patients who were prescribed an opioid analgesic in
the past year did not differ significantly from those who were
not, except for reports of severe pain in the past week
(58.1% vs. 32.8%; p<0.004).
The mean age of PCPs was 47 (Table 2). Among the PCPs,
45.9% were female, and 80.3% were white. The majority
(81.9%) of PCPs were physicians, 16.4% were NPs, and 1.6%
were PAs. Among physicians, 80.0% were internists. Of the
internists, 37.5% (n=15) were ID subspecialists and 17.5%
(n=7) were HIV specialists.
Prevalence of Opioid Analgesic Misuse and PCPs’
Judgments of Misuse
Among the 105 patients who were prescribed an opioid
analgesic, 21 (20.0%) self-reported getting high, altering the
route or selling prescription opioids in the past year (Table 3).
Of these 21 patients, 8 were African Americans (38.1%), 11
were whites (52.4%), and 2 were Hispanic/other race (9.5%)
(p=0.45).
PCPs estimated that half (49.5%) of the patients got high,
altered the route, or sold opioid analgesics in the past year. The
sensitivity of PCPs’ opinions of their patients misusing opioid
analgesics in the past year was 61.9% (95% CI 38.4% - 81.9%)
and the specificity was 53.6% (95% CI 42.4% - 64.5%) (Table 4).
PCPs did not identify 38.1% (8/21) of patients who reported
misusing opioid analgesics, and mis-identified 46.4% (39/84)
who did not report doing so. There was no concordance between
PCPs’ opinions and patients’ self-reports of misuse behaviors in
the past year (Kappa score 0.09, p=0.10).
Table 1. Patient Characteristics by Prescription Opioid Analgesic
Use in the Past Year
Characteristic Total Prescribed
Opioid
Not Prescribed
Opioid
P-Value
N=169 N=105 N=64
N (%) N (%) N (%)
Age, Mean (SD) 50.4 (7.26) 50.5 (6.95) 50.2 (7.80) 0.79
Female 59 (34.9) 40 (38.1) 19 (29.7) 0.27
Race/Ethnicity
White 60 (35.5) 39 (37.1) 21 (32.8) 0.49
African American 79 (46.8) 51 (48.6) 28 (43.8)
Hispanic 17 (10.1) 8 (7.6) 9 (14.1)
Other/Mixed 13 (7.7) 7 (6.7) 6 (9.4)
Education
Less Than High School 49 (29.2) 32 (30.8) 17 (26.7) 0.82
High School 75 (44.6) 46 (44.2) 29 (45.3)
More Than
High School
44 (26.2) 26 (25.0) 18 (28.1)
Residential History
Lifetime History
of Homelessness
136 (81.9) 87 (84.5) 49 (77.8) 0.28
Lifetime History of
Being Jailed
149 (88.2) 96 (91.4) 53 (82.8) 0.09
Lifetime History of
Being in Prison
25 (15.7) 17 (17.4) 8 (13.1) 0.48
Mean Monthly
Income
$919 $930 $900 0.59
Insurance
Medicaid/Medicare 89 (52.7) 57 (54.3) 32 (50.0) 0.58
AIDS Drug
Assistance Program
69 (42.1) 40 (39.6) 29 (46.0) 0.42
Uninsured 10 (5.9) 5 (4.8) 5 (7.8) 0.42
Depression
Moderate to Severe
(BDI Score >19)
47 (26.6) 33 (31.4) 12 (18.8) 0.07
Average Intensity of Chronic Pain, Past 7 Days
Mild 44 (26.0) 20 (19.1) 24 (37.5) 0.004
Moderate 43 (25.4) 24 (22.9) 19 (29.7)
Severe 82 (48.5) 61 (58.1) 21 (32.8)
Smoking
Lifetime
Smoking History
142 (84.0) 89 (84.8) 53 (82.8) 0.74
Lifetime History of Substance Abuse or Dependence
*
Cocaine 97 (59.2) 59 (58.4) 38 (60.3) 0.81
Methamphetamine 67 (40.6) 38 (37.3) 29 (46.0) 0.27
Heroin 49 (29.9) 29 (28.7) 20 (31.8) 0.68
Lifetime History of Substance Use
†
Cocaine 128 (77.1) 81 (78.6) 47 (74.6) 0.55
Methamphetamine 95 (57.2) 56 (54.4) 39 (61.9) 0.34
Heroin 75 (45.2) 49 (47.6) 26 (41.3) 0.43
* DIS-IV diagnosis of lifetime cocaine, methamphetamine and heroin
abuse or dependence
† DIS-IV diagnosis of lifetime cocaine, methamphetamine and heroin use
Table 2. Characteristics of Primary Care Providers (N=61)
Characteristic N (%)
Age, Mean (SD) 46.7 (8.3)
Female 28 (45.9)
Race/Ethnicity
White 49 (80.3)
African American 1 (1.6)
Hispanic 5 (8.2)
Asian or Pacific Islander 6 (9.8)
Clinical Training
Physician 50 (81.9)
Nurse Practitioner 10 (16.3)
Physician Assistant 1 (1.6)
Specialty for Physicians
Internal Medicine 40 (80.0)
Family Practice 7 (14.0)
Other 3 (5.0)
Subspecialty for Physicians
Infectious Disease 15 (37.5)
HIV 7 (17.5)
Other 2 (5.0)
Years in Clinical Practice
4-9 years 11 (18.0)
10-19 years 31 (50.8)
≥20 years 19 (31.2)
Table 3. Self-Reported Prevalence of Prescription Opioid Analgesic
Misuse in the Past Year (N=105)
N (%)
Used opioid analgesic to get high 13 (12.4)
Sold opioid analgesic 10 (9.5)
Snorted, crushed, injected or smoked opioid analgesic 5 (4.8)
Licked or dissolved opioid analgesic 4 (3.8)
Altered the route of opioid analgesic 8 (7.6)
Exchanged opioid analgesic for sex or drugs 5 (4.8)
Stole opioid analgesic from an individual 5 (4.8)
Stole opioid analgesic from a pharmacy, hospital or clinic 2 (1.9)
Forged a prescription for opioid analgesic 4 (3.8)
Traded street drugs to get opioid analgesic 5 (4.8)
Getting high or altering the route or selling opioid analgesic 21 (20.0)
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Judgments of Substance Use
More than a third of the patients (n=45, 42.9%) self-reported
using one or more illicit substances in the past year: 34.3%
(n=36) self-reported using cocaine, 24.8% (n=26) metham-
phetamine, and 10.5% (n=11) heroin (Table 4). African Amer-
icans (37.8%) were as likely as whites (44.4%) to self-report
using one or more illicit substances in the past year (p=0.14).
PCPs estimated that 49.5% had used one or more illicit
substances in the past year. The sensitivity of PCPs’ opinions
of patients using one or more substances in the past year was
71.1% (95% CI 55.7% - 83.6%) and the specificity was 66.7%
(95% CI 53.3% - 78.3%) (Table 4). PCPs overestimated illicit
substance use in 33.3% (20/60) and underestimated in 28.9%
(13/45) of patients. PCPs’ impressions were concordant with
patients’ self-reports (Kappa score 0.37, p<0.001).
Factors Associated with PCPs’ Thinking
that Their Patients had Misused Opioids
In a multivariable regression model after adjusting for patients’
age, sex, race, and history of illicit substance use in the past
year, PCPs were more likely to think that younger patients
(Adjusted Odds Ratio (AOR) 0.89, 95% CI 0.84-0.97), African
American patients (AOR 2.53, 95% CI 1.05-6.07), and those
who had used illicit substances in the past year (AOR 3.33,
95% CI 1.35-8.20) had misused opioids (Table 5). Younger
(AOR 0.94, 95% CI 0.86-1.02) and African American (AOR
0.71, 95% CI 0.25-1.97) patients were not more likely to report
misusing opioids; but those who had used illicit substances in
the past year had three-fold higher odds of misuse than those
who had not (AOR 3.01, 95% CI 1.04-8.76).
DISCUSSION
We found that PCPs judgments of opioid analgesic misuse were
discordant with patients’ ACASI self-reports. PCPs were more
likely to overestimate misuse in younger and African American
patients. PCPs determinations of misuse were more accurate
among patients with histories of illicit substance use. To our
knowledge, this is the first study that compares PCPs’
estimates of prescription opioid misuse with patients’ ACASI
self-reports. Our study highlights the challenges of determin-
ing and monitoring opioid misuse.
We selected patients who were indigent and living in an
urban poor neighborhood to reflect a group of patients thought
to be at increased risk of misuse. Despite this, PCPs were more
likely to think that African American patients had misused
opioid analgesics, even though they were no more likely to
report misuse. Patients’ race was shown to be associated with
clinicians’ perceptions of patients’ likelihood of risk beha-
viors
16. White patients are more likely to be prescribed opioid
analgesics for the treatment of chronic pain than non-
whites;
15 though, no evidence points to a higher risk of misuse
by non-whites
7,8. Studies suggest that providers invoke racial-
ly based stereotypes when faced with clinical ambiguity or
complex medical decisions
39. In the absence of adequate
training or objective measures to determine misuse, PCPs
may have unknowingly relied on racially based clinical stereo-
types when making these assessments
16. PCPs’ lack of knowl-
edge and training on determining opioid misuse may increase
the probability of use of these stereotypes to determine patient
behaviors.
Table 4. Primary Care Providers’ Judgment of Opioid Analgesic Misuse and Illicit Substance Use in the Past Year Compared to Patients’ Self-
Reports (N=105)
Sensitivity %(TP/TP+FN)
* Specificity %(TN/TN+FP)
* Agreement % Kappa Coefficient
Opioid Analgesic Misuse
Getting high on opioids 38.5 (5/13) 67.4 (62/92) 63.8 0.03
Altering the route of opioids 37.5 (3/8) 92.8 (90/97) 88.6 0.27
†
Selling opioids 50.0 (5/10) 56.8 (54/95) 56.2 0.03
One or More Misuse Behaviors 61.9 (13/21) 53.6 (45/84) 55.2 0.09
Illicit Substance Use
Cocaine 74.3 (26/35) 71.2 (47/66) 72.3 0.43
‡
Methamphetamine 56.5 (13/23) 87.3 (69/79) 80.4 0.44
‡
Heroin 27.3 (3/11) 93.6 (87/93) 86.5 0.23
†
Used One or More Illicit Substances 71.1 (32/45) 66.7 (40/60) 68.6 0.37
‡
* Abbreviations: TP, True Positive; TN, True Negative; FP, False Positive; FN, False Negative.
† p<0.01
‡ p<0.001
Table 5. Factors Associated with Primary Care Providers’ Thinking
that Their Patients had Misused Opioid Analgesics in the Past Year
(N=105)
Factors Unadjusted
Odds Ratio 95% CI
Adjusted Odds
Ratio 95% CI
Age 0.92 (0.86-0.98)
* 0.89 (0.84-0.97)
†
Sex (ref. Women) 1.34 (0.61-2.96) 1.02 (0.42-2.43)
African American
(ref. non-African American)
1.78 (0.82-3.85) 2.53 (1.05-6.07)
‡
History of substance use
in the past year
2.10 (0.96-4.61) 3.33 (1.35-8.20)
§
* p<0.01
† p<0.004
‡ p<0.04
§ p<0.009
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higher risk of misuse. Younger age was found to be a
consistent predictor of opioid misuse among the general
patient population
7,8,37. However, younger age was not asso-
ciated with misuse in our study. Uniformly applying estab-
lished predictors without contextualizing to the target patient
population might result in erroneous conclusions.
PCPs’ identification of illicit substance use was better than
that of prescription opioid analgesic misuse. Tools such as
urine toxicology screens are easier to interpret for presence of
illicit substances than for assessing prescription opioid mis-
use. Illicit substance use in the past year was associated with
patients’ self-reports of opioid misuse. These findings are
supported by prior studies that showed that illicit substance
use was one of the most reliable predictors of future prescrip-
tion opioid misuse in clinic-based samples
7,9.
Given the difficulty in making these assessments, several
risk stratification tools have been developed to help providers
identify patients at risk for misuse, though none of these tools
have been validated in high-risk patients seen in primary care
clinics
17,18,21–23. In the absence of a single, gold-standard test
for determining opioid analgesic misuse, PCPs need to be
conscious of their preconceptions and substantiate their
clinical judgments of misuse with all available tools. Studies
that examine the predictive validity as well as applicability of
these tools to primary care providers caring for high-risk
patients are needed.
The high-risk patients in our study were representative of
those who are disproportionately affected by chronic pain and
co-occurring substance use disorders
4,40 and are routinely
treated in primary care practices that lack the resources of
specialty pain clinics. Therefore, identifying better strategies to
monitor opioid misuse and providing additional resources for
patients with co-occurring substance use disorders is impor-
t a n tg i v e nr i s i n gr a t e so fo p i o i dm i s u s ea n dt h es e r i o u s
consequences of overdose
41,42.
We note several limitations. We relied on patients’ self report
as the ‘gold standard’, which may have underestimated the
prevalence of opioid analgesic misuse and illicit substance use.
This may have lead to misclassification bias. We tried to
minimize underreporting by using ACASI technology, which
reduces barriers in reporting sensitive information
30,43. While
self-reports may have lead to underreporting, other methods
such as urine toxicology screens are similarly imperfect. A
recent systematic review concluded that there was inadequate
evidence to support using urine toxicology tests to determine
opioid misuse, and highlighted the difficulty of using ‘objective’
data for measuring misuse
24,25. Despite our overall good
response rate for PCPs, we did not have information on non-
responders, thus introducing a potential for selection bias.
Our patients were poor, HIV-infected, from one urban area,
and had high rates of chronic pain and illicit substance use,
limiting the generalizability of our findings. However, these
findings may be applicable to other urban, poor, non-HIV
infected patient populations with a high burden of chronic
pain, depression, and substance use disorders
44–46.
Our study had several strengths. Patients were recruited
systematically from high-risk communities, and from these, we
selected those who were prescribed opioid analgesics. We mini-
mized recall bias by obtaining self-reports in the past 90 days
instead of the past year. Patients reported misuse using ACASI at
a community-based research site separate from clinical settings.
WerecruitedPCPsfromdiverseclinicalsettingsincludinggeneral
and HIV specific community health clinics, private practices and
university-affiliated medical practices.
We found that PCPs’ assessments of opioid misuse were
discordant with patients’ self-reports and appeared to factor
patients’ age and race incorrectly. As use and misuse of these
medications continue to rise, PCPs will need more reliable
means of determining misuse. Increasing awareness among
PCPs about the harmful effects of racially based heuristic
shortcuts on clinical assessments of misuse and providing
education on contextualizing risk and incorporating individual
patient experiences may improve the accuracy of estimates of
misuse.
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